To examine the effect of ureteral access sheath (UAS) on the expression of the pro-inflammatory mediators cyclooxygenase-2 (COX-2) and tumor necrosis factor-α (TNF-α) in the ureteral wall.
Material and Methods:
In 22 pigs an UAS was inserted and removed after 2 minutes on one side and 2 hours on the contralateral side. Postoperatively ureters were excised in vivo, and tissue samples from the distal (2 minutes/2 hours) and proximal ureter (2 minutes/2 hours) were snap-frozen before quantitative polymerase chain reaction analysis of COX-2 and TNF-α. Five unmanipulated ureteral units from other pigs served as the control group.
Results:
Compared to controls COX-2 mRNA was significantly upregulated in all UAS treated ureteral groups. Similarly, TNF-α mRNA was upregulated in all groups except the 2-minute proximal ureteral group. Both COX-2 and TNF-α expression were significantly higher in the distal than in the proximal ureter in the UAS treated ureters. After UAS insertion for 2 minutes, expression levels in the distal ureter were increased 6.5- and 8-fold for COX-2 and TNF-α, respectively; and after 2 hours of UAS placement COX-2 and TNF-α mRNA expression levels were increased 9- and 9.5-fold, respectively.
Conclusion:
The pro-inflammatory mediators COX-2 and TNF-α were significantly upregulated in the ureteral wall by the influence of UAS. These findings may have implications for postoperative pain, drainage, and complications.
Get full access to this article
View all access options for this article.
References
1.
AugeBK, PietrowPK, LallasCD, RajGV, Santa-CruzRW, PremingerGM. Ureteral access sheath provides protection against elevated renal pressures during routine flexible ureteroscopic stone manipulation. J Endourol, 2004; 18:33–36.
2.
KourambasJ, ByrneRR, PremingerGM. Does a ureteral access sheath facilitate ureteroscopy?. J Urol, 2001; 165:789–793.
3.
KaplanAG, LipkinME, ScalesCDJ, PremingerGM. Use of ureteral access sheaths in ureteroscopy. Nat Rev Urol, 2016; 13:135–140.
4.
MongaM, BhayaniS, LandmanJ, ConradieM, SundaramCP, ClaymanRV. Ureteral access for upper urinary tract disease: The access sheath. J Endourol, 2001; 15:831–834.
5.
TraxerO, ThomasA. Prospective evaluation and classification of ureteral wall injuries resulting from the insertion of a ureteral access sheath during retrograde intra-renal surgery (RIRS). J Urol, 2012; 189:580–584.
6.
OstherPJS, PedersenKV, LildalSK, PlessMS, AndreassenKH, OstherSS, et al.Pathophysiological aspects of ureterorenoscopic management of upper urinary tract calculi. Curr Opin Urol, 2015; 26:63–69.
NakadaSY, JerdeTJ, JacobsonLM, SabanR, BjorlingDE, HullettDA. Cyclooxygenase-2 expression is up-regulated in obstructed human ureter. J Urol, 2002; 168:1226–1229.
9.
NørregaardR, JensenBL, TopcuSO, NielsenSS, WalterS, DjurhuusJC, et al.Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. Kidney Int, 2006; 70:872–881.
10.
SterrettSP, WilkinsonER, JerdeTJ, MellonWS, NakadaSY. Evaluation of urothelial stretch-induced cyclooxygenase-2 expression in a mouse ureteral obstruction model. J Endourol, 2009; 23:541–544.
11.
JerdeTJ, MellonWS, BjorlingDE, NakadaSY. Evaluation of urothelial stretch-induced cyclooxygenase-2 expression in novel human cell culture and porcine in vivo ureteral obstruction models. J Pharmacol Exp Ther, 2006; 317:965–972.
12.
SchwentnerC, OswaldJ, LunacekA, PelzerAE, FritschH, SchlenckB, et al.Extracellular microenvironment and cytokine profile of the ureterovesical junction in children with vesicoureteral reflux. J Urol, 2008; 180:694–700.
NakadaSY, JerdeTJ, BjorlingDE, SabanR. Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: A better alternative for renal colic?. J Urol, 2000; 163:607–612.
15.
MisseriR, MeldrumKK. Mediators of fibrosis and apoptosis in obstructive uropathies. Curr Urol Rep, 2005; 6:140–145.
16.
MeldrumKK, MeldrumDR, MengX, AoL, HarkenAH. TNF-alpha-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion. Am J Physiol Heart Circ Physiol, 2002; 282:540–546.
17.
TraxerO, Wendt-NordahlG, SodhaH, RassweilerJ, MeretykS, TefekliA, et al.Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study. World J Urol, 2015; 33:2137–2144.
18.
DinlencCZ, LiatsikosEN, SmithAD. Ureteral ischemia model: An explanation of ureteral dysfunction after chronic obstruction. J Endourol, 2002; 16:47–50.
19.
DjurhuusJC. Aspects of Renal Pelvic Function. Thesis, Copenhagen: University of Copenhagen, 1980.
20.
HammadFT, LammersWJ, StephenB, LubbadL. Propagation of the electrical impulse in reversible unilateral ureteral obstruction as determined at high electrophysiological resolution. J Urol, 2011; 185:744–750.
21.
RoseJG, GillenwaterJY. Effects of obstruction on ureteral function. Urology, 1978; 12:139–145.
22.
MeldrumKK. Pathophysiology of Urinary Tract Obstruction, 11th ed. Campbell-Walsh Urology. Elsevier Inc., pp. 1089–1103..
23.
AnderssonKE, FormanA. Effects of prostaglandins on the smooth muscle of the urinary tract. Acta Pharmacol Toxicol (Copenh), 1978; 43:90–95.
24.
LowryPS, JerdeTJ, BjorlingDE, MaskelJL, NakadaSY. Obstruction alters the effect of prostaglandin E2 on ureteral contractility. J Endourol, 2005; 19:183–187.
25.
ColeRS, FryCH, ShuttleworthKE. The action of the prostaglandins on isolated human ureteric smooth muscle. Br J Urol, 1988; 61:19–26.
26.
ParenteL, PerrettiM. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: Two enzymes in the spotlight. Biochem Pharmacol, 2003; 65:153–159.
27.
ChaignatV, DanuserH, StoffelMH, Z'brunS, StuderUE, MevissenM. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol, 2008; 154:1297–1307.
BantisA, TsakaldimisG, ZissimopoulosA, GiannakopoulosS, KalaitzisC, PitiakoudisM, et al.Can tumor necrosis factor-α and interleukin-6 be used as prognostic markers of infection following ureteroscopic lithotripsy?. ISRN Urol, 2014; 2014:1–5.
30.
ParkJM, YangT, ArendLJ, SchnermannJB, PetersCA, FreemanMR, et al.Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am J Physiol, 1999; 276:129–136.
31.
ChuangY-H, ChuangW-L, HuangS-P, HuangC-H. Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy. Eur J Pharmacol, 2007; 569:126–137.
32.
LeeSY, LeeMY, ParkSH, KimTH, MoonYT, HanJH, et al.NS-398 (a selective cyclooxygenase-2 inhibitor) decreases agonist-induced contraction of the human ureter via calcium channel inhibition. J Endourol, 2010; 24:1863–1868.
33.
MastrangeloD, WisardM, RohnerS, LeisingerH, IselinCE. Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res, 2000; 28:376–382.
